CARsgen Therapeutics Holdings Croissance future

Future contrôle des critères 2/6

CARsgen Therapeutics Holdings devrait augmenter ses bénéfices et son chiffre d'affaires de 24.6% et de 114.3% par an respectivement. Le BPA devrait croître de de 25% par an. Le rendement des capitaux propres devrait être -97% dans 3 ans.

Informations clés

24.6%

Taux de croissance des bénéfices

25.0%

Taux de croissance du BPA

Biotechs croissance des bénéfices	42.2%
Taux de croissance des recettes	114.3%
Rendement futur des capitaux propres	-97.0%
Couverture par les analystes	Low
Dernière mise à jour	30 Oct 2024

Mises à jour récentes de la croissance future

Recent updates

Prévisions de croissance des bénéfices et des revenus

SHSC:2171 - Estimations futures des analystes et données financières antérieures (CNY Millions )
Date	Recettes	Les revenus	Flux de trésorerie disponible	Cash from Op	Moy. Nombre d'analystes
12/31/2026	2,162	-328	N/A	N/A	2
12/31/2025	720	-622	N/A	N/A	2
12/31/2024	112	-694	N/A	N/A	2
6/30/2024	6	-695	-575	-569	N/A
3/31/2024	3	-721	-520	-512	N/A
12/31/2023	N/A	-748	-464	-455	N/A
9/30/2023	N/A	-834	-480	-465	N/A
6/30/2023	N/A	-920	-495	-474	N/A
3/31/2023	N/A	-906	-638	-559	N/A
12/31/2022	N/A	-892	-782	-643	N/A
9/30/2022	13	-810	-846	-640	N/A
6/30/2022	26	-727	-910	-637	N/A
3/31/2022	26	-2,736	-800	-575	N/A
12/31/2021	26	-4,744	-691	-512	N/A
9/30/2021	13	-4,831	-540	-431	N/A
6/30/2021	N/A	-4,917	-390	-350	N/A
3/31/2021	N/A	-2,991	-352	-323	N/A
12/31/2020	N/A	-1,064	-314	-295	N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: 2171 devrait rester non rentable au cours des 3 prochaines années.

Bénéfices vs marché: 2171 devrait rester non rentable au cours des 3 prochaines années.

Croissance élevée des bénéfices: 2171 devrait rester non rentable au cours des 3 prochaines années.

Chiffre d'affaires vs marché: Le chiffre d'affaires de 2171 ( 114.3% par an) devrait croître plus rapidement que le marché Hong Kong ( 7.8% par an).

Croissance élevée des revenus: Le chiffre d'affaires de 2171 ( 114.3% par an) devrait croître plus rapidement que 20% par an.

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: 2171 devrait être non rentable dans 3 ans.

CARsgen Therapeutics Holdings Croissance future

Future contrôle des critères 2/6

Informations clés

Mises à jour récentes de la croissance future

CARsgen Therapeutics Holdings Limited Provides Consolidated Earnings Guidance for the Six Months Ended June 30, 2022

Recent updates

CARsgen Therapeutics Holdings Limited Announces That the U.S. Food and Drug Administration (FDA) Loses the Clinical Holds on Clinical Trials of Zevor-Ccel

Carsgen Therapeutics Holdings Limited Submits Application to Request Lifting Clinical Holds to FDA

CARsgen Therapeutics Holdings Limited Announces Completion of Enrollment of Confirmatory Phase II Clinical Trial of Satricabtagene Autoleucel in China

CARsgen Therapeutics Holdings Limited to Report First Half, 2024 Results on Aug 28, 2024

New minor risk - Share price stability

Non-Executive Director recently bought HK$903k worth of stock

Carsgen Therapeutics Holdings Limited Provides Updated Research Results on SATRI-CEL in Nature Medicine And At the 2024 Asco Annual Meeting

Non-Executive Director recently bought HK$937k worth of stock

CARsgen Therapeutics Holdings Limited Submits Responses to FDA Observations

CARsgen Therapeutics Holdings Limited, Annual General Meeting, May 21, 2024

CARsgen Therapeutics Holdings Limited to Report Fiscal Year 2023 Results on Mar 26, 2024

Carsgen Therapeutics Holdings Limited Announces Updated Clinical Research Results on CT041 at 2024 ASCO GI Meeting

CARsgen Therapeutics Holdings Limited Announces CT011 Achieve Investigational New Drug (IND) Clearance from the National Medical Products Administration

CARsgen Therapeutics Holdings Limited Announces Updated Research Results on Zevor-cel At 2023 American Society of Hematology Annual Meeting

CARsgen Therapeutics Holdings Limited Receives Investigational New Drug Clearance from the FDA for the Treatment of Patients with Relapsed/Refractory Multiple Myeloma

CARsgen Therapeutics Holdings Limited Announces Abstract of Zevorcabtagene Autoleucel Accepted for Poster at 2023 Ash Annual Meeting

CARsgen Therapeutics Holdings Limited Car-Gpc3 T-Cell Therapy for Advanced Hepatocellular Carcinoma: Two Patients Achieved over 7 Years of Disease-Free Survival

CARsgen Therapeutics Holdings Limited to Report First Half, 2023 Results on Aug 22, 2023

CARsgen Therapeutics Holdings Limited Appoints Xiangke Zhao as Independent Non-Executive Director and the Chairperson of the Audit Committee

Carsgen Therapeutics Holdings Limited Announces Resignation of Tak Young So as an Independent Non-Executive Director and Chairman of the Audit Committee

CARsgen Therapeutics Holdings Limited Initiates Patient Enrollment for Phase 2 Clinical Trial for CT041

CARsgen Therapeutics Holdings Limited's CLDN18.2 Mab Ab011 Achieves IND Clearance from the NMPA for the First-Line Combination Treatment of Gastric Cancer

CARsgen Therapeutics Holdings Limited Presents Results on Anti-Claudin18.2-mAb AB011 at ASCO GI

CARsgen Therapeutics Holdings Limited Announces Resignation of Chunhai FAN as Independent Non-Executive Director

Insider recently sold HK$14m worth of stock

CARsgen Presents Data from China Pivotal Phase II Trial of BCMA CAR T Zevor-cel (CT053) at 2022 ASH Annual Meeting

Less than half of directors are independent

CARsgen Therapeutics Holdings Limited Appoints Sylvie Peltier as Senior Vice President of Global Regulatory Affairs

CARsgen Therapeutics Holdings Limited Announces NDA Acceptance of BCMA CAR T Zevor-cel (CT053) by China NMPA

Carsgen Therapeutics Holdings Limited Releases First Clinical Batch from the RTP GMP Manufacturing Facility in North Carolina

CARsgen Therapeutics Holdings Limited Announces Case Report of Long Term Complete Response in Hepatocellular Carcinoma to It's GPC3 CAR T Cells (CT011) Published in Frontiers in Immunology

CARsgen Therapeutics Holdings Limited to Report First Half, 2022 Results on Aug 23, 2022

CARsgen Therapeutics Holdings Limited Announces Appointment of Dr. Hua JIANG as Executive Director

CARsgen Therapeutics Holdings Limited Provides Consolidated Earnings Guidance for the Six Months Ended June 30, 2022

Insider recently sold HK$8.8m worth of stock

Insider recently sold HK$14m worth of stock

Insider recently sold HK$1.9m worth of stock

Insider recently sold HK$10m worth of stock

Carsgen TheCARsgen Therapeutics Holdings Limited Presents Updated Data for CT041 Claudin18.2 CAR T-cells in Solid Tumors at ASCO 2022

CARsgen Therapeutics Holdings Limited Announces Resignation of Zhao Yachao as Non-Executive Director

Insider recently sold HK$3.0m worth of stock

CARsgen Therapeutics Holdings Limited Announces Results of the Investigator-Initiated Trial of CT041 Were Reported in the Nature Medicine

Less than half of directors are independent

CARsgen Therapeutics Holdings Limited, Annual General Meeting, May 25, 2022

Carsgen Therapeutics Holdings Limited Appoints Dr. Raffaele Baffa as Chief Medical Officer

Insufficient new directors

Prévisions de croissance des bénéfices et des revenus

Prévisions de croissance des analystes

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

Découvrir les entreprises en croissance